Compare PLSM & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSM | EVGN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 11.1M |
| IPO Year | 2025 | 2013 |
| Metric | PLSM | EVGN |
|---|---|---|
| Price | $1.57 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.1K | ★ 113.7K |
| Earning Date | 08-31-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $81.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.35 |
| 52 Week High | $12.97 | $1.28 |
| Indicator | PLSM | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.79 | 43.02 |
| Support Level | N/A | $0.36 |
| Resistance Level | $2.64 | $0.41 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 53.55 |
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.